Treace Medical Concepts (TMCI) is jumping 7.5% after investment bank BTIG upgraded the shares to Buy from Neutral. Why BTIG ...

BTIG analyst Ryan Zimmerman upgraded Treace Medical (TMCI) to Buy from Neutral with a $16 price target The company has pivoted away from ...

Concepts Inc (NASDAQ:TMCI) received an upgrade from BTIG, with analyst Ryan Zimmerman changing the stock rating from Neutral to Buy and setting a new price target of $16.00. This upgrade comes after a ...

BTIG analyst Ryan Zimmerman upgraded Treace Medical Concepts (TMCI – Research Report) to a Buy today and set a price target of $16.00. The ...

Treace Medical Concepts, Inc.’s TMCI share price has surged by 10.21%, which has investors questioning if this is right time to sell.

Treace Medical Concepts, Inc. has announced the limited market release of its new Percuplasty™ Percutaneous 3D Bunion Correction® System, following successful initial surgical cases.

PONTE VEDRA, Fla., Jan. 30, 2025 (GLOBE NEWSWIRE) -- (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and ...

Treace Medical Concepts, Inc. PONTE VEDRA, Fla., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company ...

Treace Medical Concepts, Inc. engages in the design, manufacture, and marketing of orthopedic medical devices and biologic solutions. It offers Lapiplasty, a bunion surgery for three-dimensional ...

Truist raised the firm’s price target on Treace Medical (TMCI) to $8.40 from $7 and keeps a Hold rating on the shares as part of a broader research note previewing 2025 in Medical Technology.